Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 3/20 | 0.35 |
| ▸ | CES1 | P23141 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1196525 | 0.83 | DGAT1 (0.46) | DGAT1CES2CES1ALDH1A1MAPT | |
| SCHEMBL730792 | 0.81 | ALB (0.41) | CES2CES1ALDH1A1KDM4EHPGD | |
| SCHEMBL12970754 | 0.80 | ALDH1A1 (0.38) | DGAT1ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL3835497 | 0.79 | PRSS1 (0.31) | KMT2A | |
| SCHEMBL7246452 | 0.79 | SMN1; SMN2 (0.36) | CES2CES1ALDH1A1HPGDTSHR | |
| SCHEMBL3165597 | 0.77 | NPC1 (0.43) | DGAT1CES2CES1ALDH1A1MAPT | |
| SCHEMBL4488041 | 0.77 | IKBKB (0.40) | ALDH1A1MAPTKDM4EHPGDTSHR | |
| SCHEMBL11004280 | 0.77 | SIRT3 (0.47) | ALDH1A1MAPTKDM4EHPGDTSHR | |
| SCHEMBL4116744 | 0.77 | KDM4E (0.50) | ALDH1A1MAPTKDM4EHPGDTSHR | |
| SCHEMBL5777262 | 0.75 | ERN1 (0.38) | DGAT1ALDH1A1MAPTKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295157-A1 | 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-09-21 | — | — | US | claimed |
| EP-4185588-A1 | 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS | Janssen Pharmaceutica NV (BE) | 2023-05-31 | — | — | EP | claimed |
| CN-116134035-A | 3- (1H-imidazol-2-yl) -2,3,8 a-tetrahydroindol-5 (1H) -one derivatives useful as factor XIA inhibitors | 詹森药业有限公司 | 2023-05-16 | — | — | CN | claimed |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | claimed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | claimed |
| CN-108419435-A | Compound and epigenetics for treating cancer | 新加坡科技研究局 | 2018-08-17 | — | — | CN | claimed |
| US-9682940-B2 | Indazole derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-20 | — | — | US | claimed |
| WO-2017061957-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-04-13 | — | — | WO | claimed |
| WO-2017034872-A1 | INDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | WO | claimed |
| US-20170057925-A1 | INDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | US | claimed |
| US-7915424-B2 | Analgesics; anxiolytic agents | ELI LILLY AND COMPANY (US) | 2011-03-29 | — | — | US | claimed |
| EP-1729771-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-10-14 | — | — | EP | claimed |
| US-20080194647-A1 | Pyridyl Derivatives and Their Use as Mglu5 Antagonists | ELI LILLY AND COMPANY (US) | 2008-08-14 | — | — | US | claimed |
| EP-1729771-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2006-12-13 | — | — | EP | claimed |
| WO-2005094822-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-10-13 | — | — | WO | claimed |
| US-20240217969-A1 | SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-07-04 | — | — | US | disclosed |
| EP-4313971-A1 | SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2024-02-07 | — | — | EP | disclosed |
| US-20080194647-A1 | Pyridyl Derivatives and Their Use as Mglu5 Antagonists | ELI LILLY AND COMPANY (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1729771-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094822-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | SMYD3, SMYD2, EHMT1 | DGAT1 1762/4885CES2 566/4885CES1 239/4885 |
| US-20230295157-A1 | 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS | SERPINC1, F11, TFPI2 | DGAT1 3600/4885CES2 4062/4885CES1 534/4885 |
| US-20240217969-A1 | SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | CDC7, CDK7, CDK17 | DGAT1 4410/4885CES2 3354/4885CES1 2508/4885 |
| US-20080194647-A1 | Pyridyl Derivatives and Their Use as Mglu5 Antagonists | HRH4, CNR2, CNR1 | DGAT1 2650/4885CES2 369/4885CES1 770/4885 |
| US-20170057925-A1 | INDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | DGAT1 706/4885CES2 273/4885CES1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.